16 hrs ago
The Zacks Analyst Blog Highlights:GIlead, AbbVie, MannKind, Alkermes and Pharmacyclics
Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Trending on the Topix Network
21 hrs ago
Individual Investor Portfolio Update: Rebalanced And Geared Up For The Long-Term
Sufficient cash is available in the event a market correction occurs in the near-term, or other opportunities present themselves.
Wed Apr 16, 2014
Pharmacyclics Files Supplemental New Drug Application for Imbruvica with Phase III CLL Study Data
IMBRUVICA is being jointly developed and commercialized by , the results of the RESONATE study demonstrated a statistically significant improvement in progression-free survival, the primary endpoint of the study, in patients treated with IMBRUVICA.
A Lucky Drug Made Pharmacyclics' Robert Duggan A Billionaire. Will Long-Term Success Follow?
Robert Duggan was enjoying just your average Tampa vacation-a visit to the headquarters of the Church of Scientology, to which he's a major donor, and a double date with one of the world's top supermodels-when a board member at Pharmacyclics , a biotechnology company he had invested in, interrupted the party with some urgent news.
Tue Apr 08, 2014
The Motley Fool
Today's Top Biotech Stories: Takeda, Eli Lilly, Immunomedics, and Pharmacyclics
Takeda Pharmaceutical and Eli Lilly have just been ordered to pay a combined $9 billion in punitive damages, after a Louisiana court ruled that the companies intentionally hid the cancer risks of their diabetes drug, Actos.
Pharmacyclics Receives Average Recommendation of "Buy" from Brokerages
Shares of Pharmacyclics have earned an average rating of "Buy" from the seventeen analysts that are presently covering the company, Stock Ratings News reports .
Tue Apr 01, 2014
Tuesday's ETF Movers: BBH, IDU
In trading on Tuesday, the Biotech ETF is outperforming other ETFs, up about 2.3% on the day.
Mon Mar 31, 2014
Three Oversold BioTechs for Tired Gamblers: StockTwits.com
NEW YORK -- Investing in the biotech sector this past year has been akin to playing all-in blackjack with the FDA as dealer.
Fri Mar 28, 2014
RDInvesting Provides Investors with Free In-Depth Equity Reports on...
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events.
Thu Mar 27, 2014
Silicon Alley Insider
Morgan Stanley Just Published A Huge Biotech Stock Report Forecasting ...
Investors and traders have been chattering about biotech stocks lately. Even after a recent 10% drop, the sector is still up by around 200% since its bull market began in 2011.
Thu Mar 20, 2014
Investor's Business Daily
Pharmacyclics Drug Imbruvica Beats Rivals: Nomura
Somaiya wrote that his survey of 30 doctors treating more than 1,600 CLL patients "highlighted rapid transition of the CLL market to newer oral drugs, in particular PCYC's Imbruvica," which was launched by Pharmacyclics and He wrote that the doctors generally thought Imbruvica is better than idelalisib, Gilead's drug that is awaiting approval, but ... (more)